MISSISSAUGA, Ontario / Feb 15, 2023 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has completed the First Closing of Secured Convertible Debentures previously announced in its Press Release dated January 30, 2023.

The first Closing comprised issuance of three Secured Convertible Debentures for a total of $765,000. Funds have been advanced on the express basis that they will be applied specifically and only to the expenses notified to and approved by the Lenders. Interest at 8% per year is payable Quarterly. The Convertible Debentures are secured by a fixed and floating charge over all assets and undertaking of the Borrower, and have a Term expiring on December 31, 2027 and are subject to customary provisions in the event of default. The Convertible Debentures are convertible into Units at the option of the Lenders. Each Unit issued on Conversion will comprise one common share and one share purchase Warrant. The Conversion Price is $0.05 per Unit, provided that if the Conversion Right is exercised after November 18, 2023, then the Conversion Price for the remainder of the Term will be $0.10 per Unit. The Exercise Price of Warrants comprised in Units issuable on Conversion is $0.20. The subscribers for the Secured Convertible Debentures issued on the first Closing have entered into an Intercreditor Agreement with each other and with Forest Lane Holdings Limited, which already holds a $1.5 million Convertible Debenture on identical terms, so that priority and entitlement will be shared amongst all the holders on a pari passu basis. Any securities issued or issuable will be subject to a four month hold period from the original issue date of the Convertible Debentures.

About MedX Health Corp:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey.

Visit www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.